Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis
- PMID: 1424060
Collagen shields containing tobramycin for sustained therapy (24 hours) of experimental Pseudomonas keratitis
Abstract
We compared collagen shields hydrated in 1.36% tobramycin with topical 1.36% tobramycin for sustained treatment of experimental Pseudomonas keratitis in rabbits. Antibiotic therapy for a total of 24 hours was initiated 14 hours after an intrastromal injection of 10(3) logarithmic phase Pseudomonas aeruginosa. Seven groups were treated as follows: groups 1-3, collagen shields hydrated in tobramycin supplemented with topical 1.36% tobramycin drops at 4, 6, or 8 hour intervals; group 4, collagen shields hydrated in tobramycin without any further topical supplementation; group 5, topical tobramycin therapy, initially every half-hour for 4 hours, then hourly; group 6, collagen shields hydrated in balanced saline solution; and group 7, no treatment. Each group contained four eyes. The groups treated with collagen shields supplemented every 4 or 6 hours with topical tobramycin had significantly fewer colony forming units (CFU) than those receiving topical or collagen shield therapy alone (P < 0.001). The group treated with collagen shields hydrated in sterile saline had 10(7) CFU per cornea, which was not significantly different from the untreated group (P > 0.2). Collagen shields hydrated in tobramycin and supplemented with topical tobramycin were effective in sustained treatment of experimental Pseudomonas keratitis.
Similar articles
-
Pharmacokinetic considerations in the treatment of bacterial keratitis.Clin Pharmacokinet. 1994 Aug;27(2):129-49. doi: 10.2165/00003088-199427020-00005. Clin Pharmacokinet. 1994. PMID: 7955776 Review.
-
Keratotomy model of pseudomonas keratitis: gentamicin chemotherapy.Refract Corneal Surg. 1992 Jan-Feb;8(1):39-43. Refract Corneal Surg. 1992. PMID: 1554638
-
Evaluation of corneal collagen shields as a drug delivery device for the treatment of experimental Pseudomonas keratitis.Ophthalmology. 1992 Jun;99(6):889-92. doi: 10.1016/s0161-6420(92)31877-9. Ophthalmology. 1992. PMID: 1630778
-
Treatment of experimental Pseudomonas keratitis using collagen shields containing tobramycin.Arch Ophthalmol. 1988 Nov;106(11):1605-7. doi: 10.1001/archopht.1988.01060140773053. Arch Ophthalmol. 1988. PMID: 3142450
-
Device drug delivery to the eye. Collagen shields, iontophoresis, and pumps.Ophthalmology. 1991 May;98(5):725-32. doi: 10.1016/s0161-6420(91)32227-9. Ophthalmology. 1991. PMID: 2062508 Review.
Cited by
-
Pharmacokinetic considerations in the treatment of bacterial keratitis.Clin Pharmacokinet. 1994 Aug;27(2):129-49. doi: 10.2165/00003088-199427020-00005. Clin Pharmacokinet. 1994. PMID: 7955776 Review.
-
Animal models of bacterial keratitis.J Biomed Biotechnol. 2011;2011:680642. doi: 10.1155/2011/680642. Epub 2011 Jan 4. J Biomed Biotechnol. 2011. PMID: 21274270 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources